X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1655) 1655
Publication (114) 114
Conference Proceeding (72) 72
Book Chapter (22) 22
Dissertation (22) 22
Patent (22) 22
Newspaper Article (17) 17
Report (14) 14
Book Review (13) 13
Magazine Article (10) 10
Book / eBook (8) 8
Trade Publication Article (3) 3
Reference (2) 2
Technical Report (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (520) 520
female (382) 382
index medicus (376) 376
middle aged (258) 258
adult (247) 247
oncology (246) 246
aged (223) 223
male (206) 206
cancer (121) 121
chemotherapy (114) 114
ovarian cancer (107) 107
analysis (96) 96
research (91) 91
aged, 80 and over (89) 89
ovarian neoplasms - drug therapy (86) 86
care and treatment (82) 82
treatment outcome (72) 72
obstetrics & gynecology (69) 69
risk factors (66) 66
animals (63) 63
antineoplastic combined chemotherapy protocols - therapeutic use (61) 61
health aspects (61) 61
hematology, oncology and palliative medicine (59) 59
clinical trials (55) 55
adolescent (53) 53
carcinoma (52) 52
ovarian neoplasms - pathology (49) 49
young adult (49) 49
disease-free survival (48) 48
retrospective studies (48) 48
antineoplastic agents - therapeutic use (47) 47
abridged index medicus (45) 45
patients (45) 45
pharmacology & pharmacy (45) 45
neoplasm recurrence, local - drug therapy (44) 44
diagnosis (43) 43
article (41) 41
medicine & public health (41) 41
prognosis (40) 40
survival (39) 39
therapy (39) 39
tumors (38) 38
mutation (37) 37
neoplasm staging (37) 37
women (37) 37
public, environmental & occupational health (35) 35
studies (35) 35
survival analysis (35) 35
bevacizumab (34) 34
drug therapy (34) 34
risk (34) 34
biochemistry & molecular biology (33) 33
child (33) 33
antineoplastic combined chemotherapy protocols - adverse effects (32) 32
internal medicine (32) 32
medicine, general & internal (32) 32
pediatrics (32) 32
pregnancy (32) 32
quality of life (32) 32
antineoplastic agents - adverse effects (31) 31
mortality (31) 31
neoplasms - drug therapy (31) 31
prevalence (31) 31
surgery (31) 31
cisplatin (30) 30
environmental sciences (30) 30
follow-up studies (30) 30
usage (30) 30
combined modality therapy (29) 29
expression (29) 29
gynecologic-oncology-group (29) 29
obstetrics and gynecology (29) 29
paclitaxel (28) 28
prospective studies (28) 28
time factors (28) 28
cancer therapies (27) 27
clinical-trials (27) 27
management (27) 27
trial (27) 27
chemistry, medicinal (26) 26
cohort studies (26) 26
ovarian neoplasms - genetics (26) 26
solid tumors (26) 26
chemistry, organic (25) 25
children (25) 25
drug administration schedule (25) 25
gastroenterology & hepatology (25) 25
infant, newborn (25) 25
multidisciplinary sciences (25) 25
administration, oral (24) 24
antineoplastic agents (24) 24
antineoplastic agents - administration & dosage (24) 24
infectious diseases (24) 24
survival rate (24) 24
carboplatin (23) 23
chemistry (23) 23
remote sensing (23) 23
united states (23) 23
age factors (22) 22
body mass index (22) 22
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1827) 1827
French (8) 8
German (5) 5
Portuguese (4) 4
Spanish (3) 3
Japanese (2) 2
Chinese (1) 1
Norwegian (1) 1
Pushto (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
by Coleman, Robert L and Coleman, R L and Oza, Amit M and Oza, A M and Lorusso, D and Lorusso, Domenica and Aghajanian, C and Aghajanian, Carol and Oaknin, A and Oaknin, Ana and Dean, A and Dean, Andrew and Colombo, N and Colombo, Nicoletta and Weberpals, Johanne I and Weberpals, J I and Clamp, Andrew and Clamp, A and Scambia, Giovanni and Scambia, G and Leary, A and Leary, Alexandra and Holloway, Robert W and Holloway, R W and Gancedo, M Amenedo and Gancedo, Margarita Amenedo and Fong, Peter C and Fong, P C and Goh, Jeffrey C and Goh, J C and O'Malley, David M and O'Malley, D M and Armstrong, Deborah K and Armstrong, D K and Garcia-Donas, Jesus and Garcia-Donas, J and Swisher, E M and Swisher, Elizabeth M and Floquet, A and Floquet, Anne and Konecny, Gottfried E and Konecny, G E and McNeish, I A and McNeish, Iain A and Scott, C L and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, J A and Ledermann, Jonathan A and Buck, M and Friedlander, M L and Harnett, P and Kichenadasse, G and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Plante, M and Provencher, D and Welch, S and Gladieff, L and Joly, F and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Pignata, S and Sabbatini, R F and Tamberi, S and Zamagni, C and O'Donnell, A and Herraez, A Casado and Guerra, E M and Palacio, I and Romero, I and Sanchez, A and ... and ARIEL3 Investigators and ARIEL3 investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | ADP | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 799 - 808
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 928 - 936
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 22, pp. 2093 - 2104
Journal Article